Since TIGIT is also co-expressed with PD-1 on tumor-antigen-specific T cells and TILs in various cancer patients, co-targeting TIGIT and PD-L1 using bsAb may overcome resistance to anti-PD-L1 therapy and enhance the antitumor benefit in tumors showing a high expression of TIGIT, CD155, and CD112. Here, CD274 is linked to cancer.